Fua'au Su'esu'e Fou mo Ma'i Leukemia Acute Myeloid

A HOLD Fa'asa'oloto 3 | eTurboNews | eTN
Avatar a Linda Hohnholz

Ua faailoa mai e le Priothera Ltd. i le aso nei ua tuuina mai e le US Food and Drug Administration (FDA) se faatagaga e faagasolo ai le talosaga a le Kamupani Investigational New Drug (IND) e amata ai lana suʻesuʻega tāua o le Vaega 2b/3 o le mocravimod (faʻaigoa MO-TRANS).

O le a amataina e le Priothera le suʻesuʻega a le MO-TRANS i le lalolagi atoa Phase 2b / 3 i Europa, US ma Iapani, iloilo le aoga ma le saogalemu o le mocravimod e avea o se faʻaopoopoga ma le tausiga o togafitiga i tagata matutua Acute Myeloid Leukemia (AML) o loʻo feagai ma allogenic hematopoietic stem cell transplant (HSCT). ). Ole su'esu'ega a le MO-TRANS e fa'amoemoe e amata ile afa lona lua ole 2022 ma o fa'amaumauga muamua mai lenei su'esu'ega e fa'amoemoe ile fa'ai'uga ole 2024.

Allogenic stem cell transplantation e na o le pau lea o le auala e mafai ona togafitia ai gasegase AML, peitaʻi o togafitiga o loʻo iai nei o loʻo fesoʻotaʻi pea ma le maualuga o aʻafiaga, ma le maualuga o le oti. 

Florent Gros, Co-Founder ma le Pule Sili o Priothera, fai mai "O le FDA IND kiliaina e amata ai le MO-TRANS suʻesuʻega suʻesuʻega mocravimod i AML gasegase o loʻo feagai ma allogeneic HSCT o se isi faʻailoga taua mo Priothera. O loʻo matou i luga o le ala e amatalia ai lenei faʻataʻitaʻiga faʻapitoa Phase 2b / 3 ma o loʻo tulimatai atu e galulue faʻatasi ma se vaega tele o tagata suʻesuʻe fiafia i le US, Europa ma Asia, o loʻo faʻasoa la matou sini o le aumaia o le mocravimod i tagata mamaʻi e avea o se togafitiga faʻaopoopo ma tausiga. mo le AML ma isi faʻamaʻi faʻamaʻi hematologic."

E uiga i le tusitala

Avatar a Linda Hohnholz

Linda Hohnholz

Faatonu sili mo eTurboNews fa'avae ile eTN HQ.

lesitala
Faasilasila i
mālō
0 faamatalaga
Manatu Faʻapena
Vaʻai manatu uma
0
E te alofa i ou mafaufauga, faamolemole taʻu mai.x
()
x
Fa'asoa i...